Tradestie Institutional Equity Comparison Engine

GBIO vs AKRO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-02-06 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

AKRO Overall Edge

AKRO Captures Institutional Edge (3โ€“1 Pillars ยท 7โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Akero Therapeutics, Inc. Common Stock (AKRO) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while GBIO counters with relative strength in Valuation. Fundamentally, GBIO trades at 7.9x Forward P/E with -2020.0% operating margin (-78.9% YoY revenue) versus AKRO at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, GBIO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against AKRO sits in UNCLASSIFIED (30th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner GBIO
GBIO 7.9x vs AKRO N/M Fwd P/E
Growth & Margin Winner AKRO
Op Margin -2020.0% vs 0.0% ยท YoY -78.9% vs +0.0%
Momentum & Technical Winner AKRO
1Y -35.8% vs +76.8% ยท 52W Pos 62% vs 90%
Options & Structure Winner AKRO
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (30th %ile IV)
GBIO NASDAQ
Generation Bio Co. Common Stock
Pharmaceutical Preparations
$5.34
-6.97% 1D
Market Cap $38.7M
1M Return -2.38%
1Y Return -35.83%
Forward P/E 7.9x
Unified AI Score
58.8 / 100 HOLD
Tech 40.0 Fund 47.0 Flow 50.0 Mom 53.9
AKRO NASDAQ
Akero Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$54.65
+0.32% 1D
Market Cap $4.5B
1M Return +1.37%
1Y Return +76.75%
Forward P/E N/M
Unified AI Score
60.0 / 100 BUY
Tech 55.0 Fund 52.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: GBIO -35.83% AKRO +76.75% Spread: +31.37 pp (AKRO Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
GBIO TTM Op. Margin: -2020.0% AKRO TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on GBIO vs AKRO. Trailing 12-month operating profitability (GBIO -2020.0% vs AKRO 0.0%) and valuation multiples (GBIO 7.9x vs AKRO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: GBIO (2) vs AKRO (7)
Institutional Metric GBIO AKRO Criterion Row Winner
Market Capitalization Scale $38.7M $4.5B Larger Scale AKRO
Trailing P/E Ratio Valuation 7.9x N/M Lower Multiple GBIO
Forward P/E Ratio Valuation 7.9x N/M Lower Multiple GBIO
Revenue Growth (YoY) Growth -78.9% +0.0% Higher Growth AKRO
Operating Margin (TTM) Profitability -2020.0% 0.0% Higher Margin AKRO
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -80.8% -34.5% Higher ROE AKRO
52-Week Range Position Momentum 62% ($0โ€“$8) 90% ($21โ€“$58) Stronger Trend AKRO
Beta / 30D Volatility Risk Regime 0.80ฮฒ ยท 26% Vol 0.90ฮฒ ยท 2% Vol Lower Realized Risk AKRO
Unified Institutional Score Composite Signal 58.8 / 100 (HOLD) 60.0 / 100 (BUY) Higher Composite AKRO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full GBIO vs AKRO Buy Guide
GBIO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live GBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
AKRO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 30th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live AKRO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither GBIO nor AKRO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.